{"id":60894,"date":"2024-02-28T07:13:40","date_gmt":"2024-02-28T07:13:40","guid":{"rendered":"https:\/\/medsname.com\/hertraz-injection\/"},"modified":"2026-04-30T14:45:56","modified_gmt":"2026-04-30T14:45:56","slug":"hertraz-injection","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/hertraz-injection\/","title":{"rendered":"Hertraz Injection"},"content":{"rendered":"
\n

Rychl\u00e1 odpov\u011b\u010f<\/h3>\n

Hertraz Injection<\/strong> je specializovan\u00fd onkologick\u00fd p\u0159\u00edpravek \u2014 pod\u00e1v\u00e1 se pod dohledem v nemocnici. P\u0159ed pou\u017eit\u00edm si p\u0159e\u010dt\u011bte odd\u00edly o d\u00e1vkov\u00e1n\u00ed, ne\u017e\u00e1douc\u00edch \u00fa\u010dinc\u00edch a interakc\u00edch; nej\u010dast\u011bj\u0161\u00ed dotazy jsou zodpov\u011bzeny v sekci FAQ na konci.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

P\u0159ehled produktu<\/strong><\/p>\n

Hertraz Injection is a medication containing the active ingredient Trastuzumab, available in vial form with a concentration of 440mg per vial. Trastuzumab is a monoclonal antibody used in the treatment of certain types of cancer, including breast cancer and gastric cancer. It is a targeted therapy that works by binding to specific receptors on cancer cells, inhibiting their growth and promoting cell death. Hertraz Injection is administered intravenously under the supervision of a healthcare professional.<\/p>\n

Pou\u017eit\u00ed<\/strong><\/p>\n

Hertraz Injection is indicated for the treatment of HER2-positive breast cancer, either alone or in combination with other chemotherapy agents. It is also used in combination with other drugs to treat HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers overexpress the human epidermal growth factor receptor 2 (HER2), and Trastuzumab specifically targets these receptors to inhibit cancer cell proliferation.<\/p>\n

Jak pou\u017e\u00edvat<\/strong><\/p>\n

Hertraz Injection is administered as an intravenous infusion by a healthcare provider in a clinical setting. The dosage and infusion rate are determined based on the patient’s body weight and medical condition. Prior to administration, the vial should be inspected visually for any particulate matter or discoloration. The injection should be given over a specified period, and patients are monitored for any signs of infusion-related reactions during and after the infusion.<\/p>\n

Jak p\u016fsob\u00ed<\/strong><\/p>\n

Trastuzumab, the active ingredient in Hertraz Injection, is a monoclonal antibody that targets and binds to the HER2 receptors present on the surface of cancer cells. By binding to these receptors, Trastuzumab inhibits downstream signaling pathways that promote cell proliferation and survival. Additionally, it can stimulate the immune system to attack HER2-positive cancer cells, further enhancing its anticancer effects. This targeted approach helps to selectively destroy cancer cells while minimizing damage to healthy tissues.<\/p>\n

D\u00e1vkov\u00e1n\u00ed a pod\u00e1n\u00ed<\/strong><\/p>\n

The recommended dosage of Hertraz Injection varies depending on the type and stage of cancer being treated, as well as other factors such as the patient’s weight and overall health. It is typically administered intravenously every 1 to 3 weeks, with the dosage adjusted based on the patient’s tolerance and response to treatment. Treatment duration may vary, and patients should follow the dosing schedule recommended by their healthcare provider.<\/p>\n

V\u00fdhody<\/strong><\/p>\n